Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. With a strong focus on infectious diseases and cancer immunotherapies, the company leverages its MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) platform technology. Bavarian Nordic aims to address unmet medical needs globally, offering a portfolio that includes vaccines for smallpox/mpox, rabies, and tick-borne encephalitis, while actively advancing candidates for diseases like RSV and COVID-19. They are deeply committed to enhancing public health and global preparedness, collaborating closely with governments and international health organizations.
The headquarters serves as the central hub for global corporate leadership, strategic planning, oversight of research and development, global commercial strategy, and core administrative functions.
Modern, purpose-built facilities designed to support advanced research, corporate management, and international collaboration, situated in a key life sciences and business area.
A dynamic, collaborative, and science-driven work environment. The culture is characterized by innovation, a strong commitment to public health, and a mission-oriented approach to tackling global health challenges.
The Hellerup headquarters is pivotal to Bavarian Nordic's worldwide operations, housing key decision-makers and coordinating the company's extensive R&D pipeline, manufacturing network, and commercialization efforts across the globe.
Bavarian Nordic maintains a significant global presence to support worldwide health initiatives. This includes research and development facilities in Europe, state-of-the-art manufacturing sites in Denmark, and commercial offices in key markets like North America and Europe. The company globally supports functions such as R&D for infectious diseases and cancer, vaccine manufacturing and supply chain management, commercial sales and marketing, regulatory affairs, and strategic partnerships with governments and health organizations to ensure broad vaccine access and pandemic preparedness.
Philip Heymans Alle 3
Hellerup
Capital Region of Denmark
Denmark
Address: Fraunhoferstraße 13, D-82152 Martinsried
Drives innovation in Bavarian Nordic's oncology pipeline and contributes to early-stage vaccine research, fostering collaborations with local and international research institutions.
Address: 430 Davis Drive, Suite 310, Morrisville, NC 27560
Manages the commercialization and distribution of Bavarian Nordic's vaccines in the crucial North American market and liaises with U.S. government agencies like BARDA for public health preparedness.
Address: Hejreskovvej 10A, DK-3490 Kvistgaard
Acts as a critical node in Bavarian Nordic's global production and supply chain, ensuring the availability of vaccines for both commercial markets and government stockpiles worldwide.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Bavarian Nordic' leadership includes:
Bavarian Nordic has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Bavarian Nordic has made strategic appointments to its executive team, notably enhancing its commercial and medical leadership with new EVPs. There was also a key departure due to role succession and another role elimination as part of strategic restructuring.
Discover the tools Bavarian Nordic uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Bavarian Nordic most commonly uses the 'firstname.lastname@bavarian-nordic.com' email format. Other potential formats could include 'firstinitiallastname@bavarian-nordic.com' or variations based on specific departments or regions, though these are less common.
[first].[last]@bavarian-nordic.com
Format
john.doe@bavarian-nordic.com
Example
85%
Success rate
Bavarian Nordic Official Website • May 8, 2024
Bavarian Nordic reported robust financial performance for the first quarter of 2024, primarily driven by strong sales of its travel vaccines Rabipur/RabAvert and Encepur. The company confirmed its financial guidance for the full year, underscoring ongoing commercial success and advancements in its product pipeline....more
Bavarian Nordic Official Website • April 24, 2024
Bavarian Nordic shared positive topline data from a pivotal Phase 3 clinical trial for its chikungunya virus-like particle (VLP) vaccine candidate, CHIKV VLP. The study demonstrated high immunogenicity and a favorable safety profile in adults and adolescents....more
Bavarian Nordic Official Website • March 6, 2024
Bavarian Nordic released its 2023 Annual Report, highlighting record financial outcomes for the year. The company experienced significant revenue growth driven by strong vaccine sales and strategic execution, positioning it for continued expansion....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Bavarian Nordic, are just a search away.